Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.49 USD | -2.05% | -25.34% | +26.26% |
Apr. 17 | North American Morning Briefing : Stock Futures -2- | DJ |
Apr. 16 | Oppenheimer Upgrades Avalo Therapeutics to Outperform From Perform, Price Target is $35 | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+26.26% | 11.88M | |
+23.37% | 47.02B | |
+48.83% | 41.86B | |
-0.94% | 41.76B | |
-5.86% | 28.8B | |
+11.29% | 26.05B | |
-20.92% | 19.15B | |
+3.20% | 12.55B | |
-2.67% | 11.82B | |
+30.23% | 12.34B |
- Stock Market
- Equities
- AVTX Stock
- News Avalo Therapeutics, Inc.
- Avalo Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Cut to $0.75 From $9, Speculative Risk Kept